A Quick Look at Today's Ratings for Penumbra(PEN.US), With a Forecast Between $315 to $330
Penumbra's Strong Growth Potential and Strategic U.S. Focus Earns 'Buy' Rating
Penumbra Is Maintained at Outperform by RBC Capital
RBC Capital Maintains Outperform on Penumbra, Raises Price Target to $330
Penumbra Is Maintained at Buy by UBS
Penumbra Price Target Raised to $330.00/Share From $315.00 by Truist Securities
Penumbra Is Maintained at Buy by Stifel
Stifel Maintains Buy on Penumbra, Raises Price Target to $318
UBS Adjusts Price Target on Penumbra to $330 From $320, Maintains Buy Rating
Penumbra Is Maintained at Overweight by Wells Fargo
A Quick Look at Today's Ratings for Penumbra(PEN.US), With a Forecast Between $318 to $340
Penumbra Is Maintained at Outperform by Baird
Penumbra Analyst Ratings
Analysts Conflicted on These Healthcare Names: Amedisys (AMED), Siemens Healthineers AG (OtherSEMHF) and Penumbra (PEN)
RBC Raises Price Target on Penumbra to $330 From $315, Keeps Outperform Rating
Cautious Hold on Penumbra Despite Strong Q1 Performance and Promising Thunderbolt Prospects
RBC Capital Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $315
BTIG Maintains Penumbra(PEN.US) With Buy Rating, Cuts Target Price to $305
Truist Financial Maintains Penumbra(PEN.US) With Buy Rating, Cuts Target Price to $315
Penumbra Is Maintained at Buy by Truist Securities